Candidate: RTB101

Type: Oral small molecule inhibitor of target of rapamycin complex 1 (TORC1), designed to inhibit the phosphorylation of multiple targets downstream of TORC1.

Status: resTORbio said May 28 it had initiated a clinical trial designed to assess whether RTB101 compared to placebo reduces the severity of lab-confirmed COVID-19 in adults 65 years of age and older who reside in a nursing home in which one or more residents or staff have developed lab-confirmed COVID-19.

Approximately 550 participants are expected to enroll in the study, in which participants will be randomized 1:1 to RTB101 10 mg once daily or matching placebo once daily. The trial’s primary endpoint is the percentage of subjects who develop lab-confirmed COVID-19 with protocol-defined progressive symptoms or are hospitalized or die through four weeks of study drug treatment.

resTORbio said the trial will be conducted with Investigators at Brown University’s Schools of Medicine and Public Health and Insight Therapeutics, and in nursing homes within the Genesis Healthcare system.

RTB101 is in clinical development phases for Parkinson’s disease (with sirolimus), neurodegenerative diseases (with rapalog), and diseases associated with TORC1 hyperactivation (also with rapalog). resTORbio reasons that since inhibition of TORC1 has been found to extend lifespan and healthspan in aging preclinical species, and improve the function of aging organ systems—including the immune system and central nervous system—RTB101 holds potential to treat aging-related diseases.


COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:

● ANTIVIRAL
● VAX
● ANTIBODY
● RNA